Literature DB >> 21302112

CML with e6a2 BCR-ABL1 transcript: an aggressive entity?

Karolien Anne Beel, Jan Lemmens, Hilde Vranckx, Johan Maertens, Peter Vandenberghe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21302112     DOI： 10.1007/s00277-011-1169-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

1.  A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms.

Authors:  Raquel Vinhas; Alexandra Lourenço; Susana Santos; Patrícia Ribeiro; Madalena Silva; Aida Botelho de Sousa; Pedro V Baptista; Alexandra R Fernandes
Journal:  Haematologica       Date:  2018-08-09       Impact factor: 9.941

2.  BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.

Authors:  Antonella Zagaria; Luisa Anelli; Nicoletta Coccaro; Giuseppina Tota; Paola Casieri; Angelo Cellamare; Luciana Impera; Claudia Brunetti; Angela Minervini; Crescenzio Francesco Minervini; Mario Delia; Cosimo Cumbo; Paola Orsini; Giorgina Specchia; Francesco Albano
Journal:  Virchows Arch       Date:  2015-07-07       Impact factor: 4.064

3.  Chronic Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring.

Authors:  Mireille Crampe; Karl Haslam; Emma Groarke; Eileen Kelleher; Derville O'Shea; Eibhlin Conneally; Stephen E Langabeer
Journal:  Case Rep Hematol       Date:  2017-10-16

4.  Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Authors:  Marte Karen Brattås; Kyrre Lilleeng; Randi Hovland; Ingvild Jenssen Lægreid; Marta Vorland; Friedemann Leh; Øystein Bruserud; Bjørn Tore Gjertsen; Håkon Reikvam
Journal:  Biomark Res       Date:  2018-11-21

5.  Atypical presentation of patients with chronic myeloid leukemia in chronic phase-Case report.

Authors:  Florian Ramdohr; Alice Fabarius; Bettina Maier; Daniela Bretschneider; Anna Jauch; Astrid Monecke; Klaus H Metzeler; Johannes W G Janssen; Richard F Schlenk; Sabine Kayser
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

6.  Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.

Authors:  Livia Manzella; Elena Tirrò; Silvia Rita Vitale; Adriana Puma; Maria Letizia Consoli; Loredana Tambè; Maria Stella Pennisi; Sandra DI Gregorio; Chiara Romano; Cristina Tomarchio; Francesco DI Raimondo; Fabio Stagno
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 7.  Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review.

Authors:  Yasuhiko Harada; Satoshi Nishiwaki; Takumi Sugimoto; Koichi Onodera; Tatsunori Goto; Takahiko Sato; Sonoko Kamoshita; Naomi Kawashima; Aika Seto; Shingo Okuno; Satomi Yamamoto; Toshihiro Iwasaki; Yukiyasu Ozawa; Koichi Miyamura; Yoshiki Akatsuka; Isamu Sugiura
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 8.  Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia.

Authors:  Matteo Molica; Elisabetta Abruzzese; Massimo Breccia
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.